NovoCure (NVCR) Short-term Investments (2014 - 2026)

NovoCure (NVCR) has reported Short-term Investments for 13 consecutive years, with $346.9 million the latest figure, recorded in Q2 2026.

• Quarterly Short-term Investments fell 54.47% year-over-year to $346.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $346.9 million (down 54.47% YoY) and the FY2025 annual result came in at $354.1 million, down 55.52% from the prior year.
• Short-term Investments improved to $346.9 million in Q2 2026 per NVCR's latest filing, from $344.5 million in the prior quarter.
• Over the last five years, Short-term Investments for NVCR reached as high as $854.1 million in Q4 2022 and fell as low as $344.5 million in Q1 2026.
• A 5-year average of $665.0 million and a median of $751.7 million in 2022 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments soared 197.82% — and 2026, when it slumped 57.04%.
• Year by year, Short-term Investments stood at $854.1 million in 2022, then fell by 21.58% to $669.8 million in 2023, then increased by 18.86% to $796.1 million in 2024, then tumbled by 55.52% to $354.1 million in 2025, then retreated by 2.05% to $346.9 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $346.9 million, $344.5 million, and $354.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.